Big Pharma Embraces Again: U.S. Bio Company Recovers Retinal Gene Therapy Asset

MeiraGTx Holdings plc (Nasdaq: MGTX), a U.S.-based gene therapy developer, reported on March 26 its fourth-quarter and full-year 2025 results, announcing that its radiation-induced xerostomia treatment AAV2-hAQP1 has received FDA Breakthrough Therapy designation and that its Parkinson’s disease program AAV-GAD is poised to enter Phase 3 following RMAT (Regenerative Medicine Advanced Therapy) designation. The company has expanded strategic partnerships, including an AI-based AAV-GAD joint venture with Hologen Neuro AI featuring approximately $200 million in upfront payments and up to $230 million in additional funding, and an ophthalmology gene therapy collaboration with Eli Lilly that brings in $75 million upfront and up to $400 million in milestones. MeiraGTx said it expects to reduce its net loss for 2025 to $114.2 million and, with operating funds secured through mid-2027, maintain the capacity to repay its Perceptive Credit-related debt. On April 15, MeiraGTx and Janssen mutually terminated their 2023 asset-sale agreement for RPGR retinal disease assets and entered a new asset-purchase agreement to reacquire those assets and rights, with both parties waiving any milestone or other payment obligations under the prior deal and agreeing not to claim unpaid amounts for past supply services.

On March 25, MeiraGTx amended its note-purchase agreement with Perceptive Credit, extending the debt maturity to May 2, 2027, and agreeing to early principal repayment of $25 million by June 30, 2026 (see sec.gov). Ahead of an April 16 corporate presentation on three-year follow-up data from the AAV2-hAQP1 Phase 1 trial, the stock jumped about 17% on April 14 on Nasdaq, reaching a 52-week high (see gurufocus.com).

MeiraGTx, headquartered in the U.K. and the U.S., is a clinical-stage gene therapy company developing AAV-based treatments and gene-expression control platforms targeting high-unmet-need indications in ocular diseases, salivary gland disorders and central nervous system conditions (see investors.meiragtx.com). In the gene therapy sector, where global pharma partnerships, AI-driven clinical development and dedicated financing are on the rise, capital structure and partnership terms are emerging alongside pipeline value as key drivers of company valuation.